<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">Primary antiphospholipid syndrome</z:e> (APS) is a disease characterized by the presence of autoantibodies reacting with proteins bound to <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, leading to <z:mp ids='MP_0005048'>thrombosis</z:mp> and gestation abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>Prothrombotic states and impaired clot dissolution are believed to contribute to the occurrence of <z:hpo ids='HP_0011010'>chronic</z:hpo> thromboembolic <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> (CTEPH) in APS </plain></SENT>
<SENT sid="2" pm="."><plain>Whether preventive anticoagulation therapy in patients with antiphospholipid autoantibodies without a history of <z:mp ids='MP_0005048'>thrombosis</z:mp> reduces the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> is currently unclear </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnosis and treatment of CTEPH in APS is similar to CTEPH complicated by other predisposing conditions, with surgical treatment being the most effective </plain></SENT>
<SENT sid="4" pm="."><plain>However, not every patient with CTEPH is suitable for pulmonary thromboendartarectomy and such individuals may benefit from pharmacotherapy of <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo>, given the presence of pulmonary microvascular abnormalities similar to those in idiopathic <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Anticoagulation therapy is the mainstay of management because of the high risk of recurrent embolization and local in-situ <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>